A comparison of the effects of adrenaline and noradrenaline in critically ill patients
| ISRCTN | ISRCTN92846592 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN92846592 |
| Protocol serial number | N/A |
| Sponsor | The St George Hospital - Dept of Intensive Care (Australia) |
| Funder | Not provided at time of registration |
- Submission date
- 12/11/2004
- Registration date
- 07/03/2005
- Last edited
- 30/10/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr John Myburgh
Scientific
Scientific
Intensive Care Unit
The St George Hospital
Gray Street
Kogarah, Sydney
2217
Australia
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study acronym | The Cat study |
| Study objectives | The aim of the Cat study is to compare the clinical effects of adrenaline and noradrenaline in critically ill patients with circulatory dysfunction or failure. It is a prospective, double blind, randomised trial. Patients will be designated a priori into two groups: circulatory failure due to sepsis syndrome/septic shock and circulatory failure due to non-septic causes (cardiogenic shock, normovolaemic hypotension, augmentation of mean arterial pressure). The null hypothesis assumes no difference in resolution of circulatory failure or all-cause mortality in patients with circulatory failure receiving infusions of either adrenaline or noradrenaline. |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Circulatory failure in critically ill patients |
| Intervention | Patients randomised to receive either adrenaline or noradrenaline |
| Intervention type | Drug |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | adrenaline or noradrenaline |
| Primary outcome measure(s) |
Time to resolution of circulatory failure to pre-morbid state from commencement of catecholamine. |
| Key secondary outcome measure(s) |
ICU length of stay and mortality, hospital mortality and 90-day mortality: degree of organ dysfunction during 28-day period (as determined by SOFA scores): cardiovascular, respiratory, renal, neurological, hepatic; and metabolic function. |
| Completion date | 31/10/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target sample size at registration | 250 |
| Key inclusion criteria | Critically ill patients requiring a catacholamine infusion for cardiovascular support |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 01/10/2003 |
| Date of final enrolment | 31/10/2005 |
Locations
Countries of recruitment
- Australia
Study participating centre
Intensive Care Unit
Kogarah, Sydney
2217
Australia
2217
Australia
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/12/2008 | Yes | No |
